Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» belzutifan
belzutifan
Merck's Welireg scores FDA nod in cancers spurred by rare disease—and its label is broader than expected
Fierce Pharma
Sat, 08/14/21 - 01:44 pm
Merck
belzutifan
Peloton Therapeutics
FDA
von Hippel-Lindau disease
Welireg
Merck wins priority review for rare carcinoma drug belzutifan, the centerpiece of $1B+ Peloton buyout
Endpoints
Tue, 03/16/21 - 10:54 am
Merck
Peloton Therapeutics
belzutifan
M&A
PT2977
renal cell carcinoma
priority review
FDA